

Ashraf A. Aly,<sup>a,b,\*</sup> Esam A. Ishak,<sup>c</sup> Musaed A. Alsharari,<sup>b</sup>  
Nayef S. Al-Muaikel,<sup>d</sup> and Tarek M. I. Bedair<sup>a</sup>

<sup>a</sup>Chemistry Department, Faculty of Science, El-Minia University, 61519 El-Minia, Egypt

<sup>b</sup>Chemistry Department, College of Science, Al-Jouf University, Al-Jouf, Sakaka, Saudi Arabia

<sup>c</sup>Chemistry Department, Faculty of Science, El-Azhar University, Assiut, Egypt


<sup>d</sup>Chemistry Department, College of Pharmacy, Al-Jouf University, Al-Jouf, Sakaka, Saudi Arabia

\*E-mail: ashrafaly63@yahoo.com

Received May 7, 2010

DOI 10.1002/jhet.639

Published online 18 October 2011 in Wiley Online Library (wileyonlinelibrary.com).



Because of the interesting biological activities of aminonaphthoquinones, in this review we survey two classes of amino-1,4-naphthoquinones: 2,3-diamino-1,4-naphthoquinone and 2-amino-1,4-naphthoquinone. The review includes synthetic methodologies for these classes in addition to their heterocyclization processes.

*J. Heterocyclic Chem.*, **49**, 9 (2012).

### Contents

	Page
1.	Introduction
2.	Discussion
2.1.	2,3-Diamino-1,4-naphthoquinone
2.1.1.	Synthesis
2.1.2.	Reactions
2.1.2.1.	Substitution reaction
2.1.2.2.	Synthesis of imidazoles
2.1.2.3.	Synthesis of thia- or seleno-diazole derivatives
2.1.2.4.	Synthesis of fused pyridine derivatives
2.1.2.4.1.	Synthesis of Discorhabdin C
2.1.2.4.2.	Synthesis of 1-aza-anthraquinones
2.1.2.5.	Synthesis of quinoxalinediones
2.1.2.6.	Synthesis of diazepine derivatives
2.2.	Chemistry of 2-amino-1,4-naphthoquinone
2.2.1.	Synthesis
2.2.2.	Reactions
2.2.2.1.	Substitution reactions
2.2.2.2.	Synthesis of pyrroles
2.2.2.3.	Synthesis of azepines derivatives
2.2.2.4.	Synthesis of indoles derivatives
2.2.2.5.	Synthesis of quinoline derivatives
2.2.2.6.	Synthesis of 1,4-dihydropyridines
2.2.2.7.	Synthesis of oxazine, tetrahydrobenzo[g]chinazoline and pyridoacridines derivatives
	References and notes

## 1. INTRODUCTION


Naphthoquinones are widely distributed in plants, fungi, and some animals. Their biological activities have been studied including their effects on prokaryotic and eukaryotic cells [1,2]. Plumbagone, juglone, and lawsone are naturally occurring naphthoquinones of plant origin that have antibacterial effects on several species of both aerobic and anaerobic organisms [3], and toxins derived from naphthazarin (5,8-dihydroxy-1,4-naphthoquinone) are produced by *Fusarium solani* and attack plants, other fungi, and bacteria [4]. The natural naphthoquinone products alkannin and shikonin and their derivatives, in general, are active against Gram-positive bacteria such as *Staphylococcus aureus*, *Enterococcus faecium*, and *Bacillus subtilis*, but are inactive against Gram-negative bacteria [5]. 2,3-Diamino-1,4-naphthoquinone itself was found to act as an antibacterial agent against *S. aureus*, with  $IC_{50}$  values ranging from 30 to 125  $\mu\text{g/mL}$ . 2,3-Diamino-1,4-naphthoquinone presented a minimal bactericidal concentration higher than 500  $\mu\text{g/mL}$ , indicating that its effect was bacteriostatic [6].

Carnivorous plants have evolved special mechanisms for trapping insects and consuming their components when grown under harsh conditions [7]. Carnivory is also characterized by the synthesis of secondary metabolites in the insect-trap tissues, which contain the aminonaphthoquinone moiety [8]. The synthesis of protecting secondary metabolites is very common in many plants and occurs in response to chemical, biotic or physical stress [8–10].

Aminonaphthoquinones, considered to be potential antifungal drugs, are also produced by many plants that belong to the Caryophyllales families [8], including Nepenthaceae [11], Droseraceae [12], Plumbaginaceae [13], Drosophyllaceae [14], and Ebenaceae [15]. *In vitro* assays showed that several 2,3-di-substituted 1,4-naphthoquinones are as effective as the clinically used antifungal drugs fluconazole and amphotericin-B [16].

In addition, the 4-aminoquinolines (chloroquine [CQ] for adults/amodiaquine for children) have been used as the first-line antimalarial drugs for many years. However, the therapeutic efficacy of the 4-aminoquinolines, particularly of CQ, has declined over the years [17] since the mid-70s [18].

Malaria is a major tropical disease, which kills 2 million people annually. As antimalarials are the major arsenal for treatment of the disease, there is an urgent need for newer drugs with novel mechanisms of action, which will be effective against all strains of the parasite. Several synthetic and natural naphthoquinones as potential antimalarial agents have identified aminonaphthoquinones, as a class of antimalarial compounds with antimalarial activity against *Plasmodium falciparum*. Among these compounds, 2-amino-3-chloro-1,4-naphthoquinone is the most potent. It had an  $IC_{50}$  of 0.18  $\mu\text{M}$  (37.3  $\text{ng mL}^{-1}$ ) against the W2 clone, and is more potent than CQ, which had an




**Figure 1.** Reactions of 1,8-diaminonaphthalene (**1**) (as a structural resembled analogous) with  $\pi$ -acceptors.

$IC_{50}$  of 0.23  $\mu\text{M}$  (72  $\text{ng mL}^{-1}$ ). It was also active against the D6 clone. In general, 2-amino-1,4-naphthoquinone analogs and the 4-amino-1,2-naphthoquinone analog showed promising antimalarial activity in the bioassay. In contrast, a number of 2-hydroxy-1,4-naphthoquinones and dimeric quinones were less active [19].


The synthesis and investigation of tumor-inhibitory activity of a series of aminonaphthoquinone derivatives of diospyrin (a bisnaphthoquinone), which was isolated from *Diospyros montana* Roxb., have been reported [20]. An aminoacetate derivative showed the maximum ( $\sim 93\%$ ) increase in life span *in vivo* against murine Ehrlich ascites carcinoma (EAC) at a dose of 1  $\text{mg kg}^{-1} \text{day}^{-1}$  (ip; five doses), and the lowest  $IC_{50}$  (0.06  $\mu\text{M}$ ) *in vitro*. Further, the same analog also exhibited considerable enhancement in antiproliferative activity when evaluated against human cell lines, *viz.*, malignant skin melanoma and epidermoid laryngeal carcinoma ( $IC_{50} = 0.06$  and 0.92  $\mu\text{M}$ , respectively) in comparison to the natural precursor, diospyrin ( $IC_{50} = 0.82$  and 3.58  $\mu\text{M}$ , respectively). Moreover, diospyrin and all its derivatives were found to show significantly greater ( $\sim 17$ - to 1441-fold) cytotoxicity against the tumor cells as compared with normal human lymphocytes. All these quinonoids generated substantial amounts of reactive oxygen species in EAC cells, more or less commensurate to their respective  $IC_{50}$  values [20].

Previously, Aly and El-Shaieb [21] investigated the reaction of 1,8-diaminonaphthalene (**1**) (as a structural resembled analogous to 2,3-diamino-1,4-naphthoquinone) with  $\pi$ -acceptors. Various heterocyclic compounds were obtained during the addition of compound **1** to 1,1,2,2-tetracyanoethylene (TCNE, **2**), 7,7',8,8'-tetracyanoquinodimethane (TCNQ, **3**), 2-dicyano-methyleneindane-1,3-dione (CNIND, **4**), 2-(2,4,7-trinitro-9H-fluoren-9-ylidene)propane-dicarbonitrile (DTF, **5**), 2,3,5,6-tetrachloro-1,4-benzoquinone (CHL-*p*, **6a**), and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, **6b**) (Fig. 1) [21]. Although most of the examples herein involve cyclization reactions of aminonaphthoquinones, a few of these expected novel syntheses of heterocycles have been reported. So, it is of interest to report on the vital target class of compounds [21].

Scheme 1



Scheme 2



## 2. DISCUSSION

In the light of the aforementioned interesting biological activities of aminonaphthoquinones, our attention is turned to investigate the routes of synthesis of 2,3-diamino-1,4-naphthoquinone and 2-amino-1,4-naphthoquinone. In addition, we report on the utility of these two substances in heterocyclization.


### 2.1. 2,3-Diamino-1,4-naphthoquinone.

**2.1.1. Synthesis.** Reaction of 2,3-dichloro-1,4-naphthoquinone (7) with 2 equiv of sodium azide produced in good yield the diazido derivative 8 [22], which was reduced with  $\text{Na}_2\text{S}_2\text{O}_4$  to give the compound 9 (Scheme 1) [23,24].


Díaz *et al.* used the published procedure [25] of the synthesis of intermediated compounds 10–12 (Scheme 2) [25]. Thereafter, addition of hydrochloric acid gas in methanol to 12 produced the corresponding salt of compound 9 as shown in Scheme 2 [25].

Winkelmann [26] reported that reaction of compound 7 with 2 equiv. of potassium phthalimide proceeded to afford diphtalimido naphthoquinone 13, which was


Scheme 3




Scheme 4



Scheme 5



Scheme 6



allowed to react with hydrazine hydrate to give compound 9 (Scheme 3) [26].

### 2.1.2. Reactions.

**2.1.2.1. Substitution reaction.** Treatment of 2,3-diamino-1,4-naphthalene-1,4-dione (9) with benzoyl chloride in chloroform afforded *N*-(3-amino-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzamide (14; Scheme 4) [27].

Similarly, reaction of compound 9 with ethyl chloroformate afforded ethyl 3-amino-1,4-dioxo-1,4-dihydronaphthalen-2-ylcarbamate (15, Scheme 5) [28].


Reaction of compound 9 with diethyl 2-(ethoxymethylene)malonate gave in good yield tetraethyl 2,2'-(1,4-dioxo-1,4-dihydronaphthalene-2,3-diyl)bis(azanediy)bis(methan-1-yl-1-ylidene)dimalonate (16) as shown in Scheme 6 [29].

Heating of compound 9 in acetic anhydride for 2 h produced 1,4-dioxo-1,4-dihydronaphthalene-2,3-diyl)diacetamide (17) as shown in Scheme 7 [28].


Benzoylation of compound 9 was achieved by refluxing 9 with 2 equiv. of benzoyl chloride in *p*-xylene for 2 h. The dibenzoyl product of 9, identified as *N,N'*-(1,4-dioxo-1,4-dihydronaphthalene-2,3-diyl)dibenzamide (18), was obtained in good yield (Scheme 8) [30].





**2.1.2.2. Synthesis of imidazoles.** Compound 9 reacted with potassium xanthogenate to give 2-thioxo-2,3-dihydro-1*H*-naphtho[2,3-*d*]imidazole-4,9-dione (19). Various

Scheme 7



Scheme 8





2-(2-oxoalkylthio)-1*H*-naphtho[2,3-*d*]-imidazole-4,9-diones **20** were obtained by the reaction of **19** with  $\alpha$ -halo carbonyl compounds as shown in Scheme 9. Eleven examples were described [30].

Reaction of compound **9** with diethyl 2-benzylidene-malonate (**21**) afforded 2-phenyl-1*H*-naphtho[2,3-*d*]imidazole-4,9-dione (**22a**) as shown in Scheme 10 [29].

Imidazole **22a** was also obtained *via* the reaction of 2-amino-3-benzoylamino-1,4-naphthoquinone (**14**) with alcoholic KOH for 3 h (Scheme 11) [30].

On refluxing a mixture of compound **9** in formic acid for 2 h, the reaction afforded in poor yield 1*H*-naphtho[2,3-*d*]imidazole-4,9-dione (**23**) as shown in Scheme 12 [30].


Aly *et al.* [31] have recently reported that imidazoles derived from compound **9** were easily directly prepared by addition of stoichiometric quantities of the appropriate aldehydes in dimethyl sulfoxide as a solvent as shown in

Scheme 13 [31]. The reaction proceeds in few hours to give mono- and bis-imidazoles **22a–g**, **25**, and **26**. That procedure can be generalized to different classes of aldehydes. 2-Methyl-1*H*-naphtho[2,3-*d*]imidazole-4,9-dione (**24**) was also obtained, by refluxing in acetic acid [31].


**2.1.2.3. Synthesis of thia- or seleno-diazole derivatives.** Compound **9** reacted with thionyl chloride or selenium oxychloride to afford the corresponding thia- or selenadiazole derivatives **27a,b** as shown in Scheme 14 [32]. Either compound **27a** and/or **27b** can then be condensed with substituted hydrazines and/or hydroxylamine hydrochloride to give compound **28a,b** and/or **29** (Scheme 14) [32].

**2.1.2.4. Synthesis of fused pyridine derivatives.**

**2.1.2.4.1. Synthesis of Discorhabdin C.** A model study designed for the total synthesis of Discorhabdin C (**30**) is presented (Fig. 2). The key reaction is the para alkylation of the phenolate derived from the dibromomesyloxy



a: R = C<sub>6</sub>H<sub>5</sub>- (85%); b: R = 4-H<sub>3</sub>C-OC<sub>6</sub>H<sub>4</sub>- (90%); c: R = 4-Cl-C<sub>6</sub>H<sub>4</sub>- (80%); d: R = 3,4-O-CH<sub>2</sub>-OC<sub>6</sub>H<sub>3</sub>- (94%); e: R = 2-Furyl (76%) and f: R = 4-[2,2]Paracyclophanyl (74%)



**Figure 2.** Synthesis of Discorhabdin C.

phenol **31**. The desired product **32** (Fig. 2) contains the tetracyclic aza-spirobicyclic system present in this class of marine alkaloids [33].

2.1.2.4.2. Synthesis of 1-aza-anthraquinones. A series of 1-aza-anthraquinones **34** were characterized, besides the expected *N*-alkylamino derivatives **35**, from the substitution reactions of 2-methoxylapachol (**33**) with primary amines. An investigation of the reaction conditions allowed reasonable selectivity in the products distribution (Scheme 15) [34].

2.1.2.5. Synthesis of quinoxalinediones. Interestingly, reaction of **9** with oxalyl chloride afforded the tetralone, which directly reacted with thionyl chloride to give the dichloride followed by Gabriel reaction to obtain compound **36**, which was directly reacted with thionyl chloride, to yield compound **37a**. The reaction of **36** with



selenium oxychloride produced compound **37b** as shown in Scheme 16 [35].


Condensation of compound **9** with 1,4-dibromobutane-2,3-dione led to 2,3-bis(bromo-methyl)-benzo[*g*]quinoxaline-5,10-dione [36], which was converted to compound **38** by classical chlorination using lithium chloride as illustrated in Scheme 17 [36].

Reaction of compound **9** with  $\alpha$ -dicarbonyl compounds afford 2,3-disubstituted benzoquinoxaline-5,10-diones **39** as shown in Scheme 18 [36].

It was reported that refluxing of compound **9** with 1,2-di(1*H*-pyrrol-2-yl)ethane-1,2-dione (**40**) in glacial acetic acid for 12 h afforded 2,3-di(1*H*-pyrrol-2-yl)-benzo[*g*]quinoxaline-5,10-dione (**41**) as illustrated in Scheme 19 [37]. Refluxing of **9** with naphthalene-1,2-dione (**42**) in 10% acetic acid for 2-3 h gave dibenzo[*a,i*]phenazine-8,13-dione (**43**, Scheme 19) [37]. Similarly reaction of **9** with phenanthrene-9,10-dione (**44**) produced tribenzo[*a,c,i*]phenazine-10,15-dione (**45**, Scheme 19) [37]. Benzo[*i*]dipyrido[3,2-*a'*:2',3'-*c*]phenazine-10,15-dione (**47**) can be obtained from the reaction of **9**.HCl with 1,10-phenanthroline-5,6-dione (**46**) in refluxing ethanol for 1.5 h (Scheme 19) [37–39].

It was indicated that different aromatic aldehydes can react with 2,3-diamino-naphthalene-1,4-diol to yield 2,3-






disubstituted 1,2,3,4-tetrahydrobenzo[*g*]-quinoxaline-5,10-diones **48** as shown in Scheme 20 [40].

Katritzky [41] and his group reported that the reaction of compound **9** with 2,3-dichloro-naphthalene-1,4-dione (**7**) in absolute ethanol afforded dibenzo[*b,i*]phenazine-5,7,12,14(6*H*,13*H*)-tetraone (**49**) as shown in Scheme 21 [41].

**2.1.2.6. Synthesis of diazepine derivatives.** Compound **9** reacted with various derivatives of diethyl malonate to afford condensed products, which in the presence of potassium hydroxide gave 3-substituted 1*H*-naphtho[2,3-*b*][1,4]diazepine-2,4,6,11(3*H*,5*H*)-tetraones **50** as illustrated in Scheme 22 [27].




A rapid route to a series of naphthoquinone-fused indole derivatives **51** (Fig. 3) *via* irradiation in a modified commercial domestic microwave was reported [42]. The desired products were produced in high yields and short reaction times. The naphthoquinone-fused indole derivatives **51** were evaluated for their proinflammatory cytokines responses using lipopolysaccharide (LPS)-stimulated RAW264.7 marine macrophages. The results showed that most of the tested compounds inhibit the production of nitric oxide (NO), prostaglandin (PG)<sub>E2</sub>,




tumour necrosis factor (TNF)- $\alpha$ , interleukin (IL)-6 and IL-1 $\beta$  in RAW264.7 cells treated with LPS [42].

Reaction of 2,3-bis(arylamino)naphthalene-1,4-diones **52** (1 equiv.), aldehydes (1.1 equiv.) and BF<sub>3</sub>.Et<sub>2</sub>O (2 equiv.) in acetonitrile afforded the diazepine derivatives **53** and **54** (Scheme 23) [43]. The reaction involves the formation of iminium ion intermediates, followed by cyclization to produce seven-membered rings (Scheme 23). Thirteen examples were described [43].

**2.2. Chemistry of 2-amino-1,4-naphthoquinone.** It was previously reported that the nucleophilicity of the amino group in **55** is greater than expected for its vinyl-ogous amide structure. Thus, 2-amino-1,4-naphthoquinone (**55**) reacts as an *N*-nucleophile with some bis-electrophiles [44]. On the other hand, Michael addition between **55** and activated unsaturated bonds is differed from those generally found in  $\beta$ -imino- $\alpha,\beta$ -unsaturated carbonyl compounds [45]. These results indicate that the mesomeric interaction between the nitrogen lone pair and the C=O group in **55** is not very important and, consequently, *C*-alkylations proceeding on the enol tautomer **55'** (Fig. 4) through the electronic interaction of the lone pair on the nitrogen atom with the quinoid structure, are less favored than in related systems. The mesomeric effect explains the shift of the E<sub>1/2</sub> value of **55** (at pH 7.0) of *ca.* 225 mV to more negative potential, as compared with unsubstituted naphthoquinone [46]. However, this value might be also explained by a



**Figure 3.** Structure of naphthoquinone-fused indole derivatives **51**.



hydrogen bond interaction between the  $C^1=O$  and  $NH_2$  groups, stabilizing the quinoid form (**55''**, Fig. 4) [47].

For instance, the intramolecular *N*-acylation of some aminoquinones has required their prior reduction to the more basic aminonaphthohydroquinone derivatives [48,49]. Lately, 2-amino-1,4-naphthoquinone (**55**) has been shown to have some reactivity with some electrophiles such as  $\beta$ -dielectrophiles [50], and methyleniminium salts (Fig. 5) [50]. In these reactions, the principal product was found to be that of *N*-alkylation. The reaction of **55** with electrophiles follows the general sequence outlined in Figure 5. The reaction follows path “a” leading to *N*-alkylated product **57** or path “b” leading to *C*-alkylated product **58**. In these reactions, the principal product was found to be that of *N*-alkylation. The reaction of **55** with electrophiles follows the general sequence outlined in Figure 5 [51].

**2.2.1. Synthesis.** 2-Amino-1,4-naphthoquinone (**55**) can be prepared by the reaction of naphthoquinone (**59**) with hydrazoic acid at  $0^\circ\text{C}$  for about 5–15 min. Compound **59** is first reduced by hydrazoic acid to the corresponding hydroquinone **60** (Scheme 24). The obtainable 2-azido hydroquinone **61**, which is in equilibrium with its keto form (**61a**  $\leftrightarrow$  **61b**), is unstable and is converted to 2-aminonaphthoquinone (**55**) or 2-azidonaphthoquinone (**62**), depending on the reaction conditions as shown in Scheme 24 [52]. The mechanism of the

formation of 2-amino-naphthoquinone is illustrated in Scheme 25 [52].

### 2.2.2. Reactions.


**2.2.2.1. Substitution reactions.** Reaction of formaldehyde with 2-amino-1,4-naphthoquinone (**55**) in chloroform at rt gives exclusively *N*-(hydroxymethyl)aminoquinone (**63**) in 64% yield (Scheme 26) [51]. There is no observed product corresponding to nucleophilic substitution at C-3 (compound **64**). This means that **55** did not act as an enamine compound and the reaction follows path “a” in Scheme 26 [51].

Reaction of **55** with simple aldehydes and ketones under neutral conditions gave *N*-(alkenyl)-aminoquinones **65a–d** in 45–56% yield (Scheme 27). Four examples were described [51].

Reaction of 2-dimethylamino-1,4-naphthoquinone (**66a**) with 2 equiv. of cyanomethylenetriphenylphosphorane afforded the adduct **67**, which was obtained through an internal elimination of triphenylphosphine from the intermediate (B) (Scheme 28) [53].

Previously, Bestmann and Lang reported that the reaction of 2-anilinophenyl-1,4-naphthoquinone (**66b**) with benzylidenetriphenylphosphorane (**68a**) yielded the respective quinonemethide **69** and triphenylphosphine oxide (TPPO) (Scheme 29) [54].

**2.2.2.2. Synthesis of pyrroles.** Reaction of 1 equiv. of 2-substituted amino-1,4-naphthoquinones **66b,c,d** with 2



**Figure 4.** Hydrogen bond interaction between the  $C=O$  and  $NH_2$  group in 2-amino-1,4-naphthoquinone (**55**).





Figure 5. Various electrophilic substitution types in **55**.





equiv. of the phosphonium ylide **68b,c** afforded the phosphorane adduct **70a-f** in good yield along with TPPO (Scheme 30) [53].

Mechanistically, quinone **66b-d** reacted with 1 mol of ylide **68** to give TPPO and the reactive olefinic intermediate (A) via a 1,2-addition, which reacted with another molecule of ylide **68** to afford the cyclic phosphorane adduct B, through loss of a suitable moiety (*i.e.*, R). That was followed by autoxidation to attain the aromaticity and therefore compounds **70a-f** were formed (Scheme 31) [53].

Reaction of 2-aminonaphthoquinones **66a-d** with active methylene compounds (2 equiv.) in the presence of manganese (III) acetate in acetic acid for 2 h afforded compounds **71** in not bad yields (Scheme 32) [54].


The proposed mechanism for the formation of **71** is outlined in Scheme 33. The addition of malonyl radical **72** to quinone ring followed by oxidation gives **73**, which undergoes lactamization to produce **71** (Scheme 33) [55].

Jiang and Chuang indicated that upon treatment of 2-(ethylamino)-1,4-naphthoquinone (**66d**) with 2,4-pentanedione and manganese (III) acetate under similar conditions, compound **76a** was obtained in 65% yield and other by-cyclized products **77** and **78** (Scheme 34) [56]. Oxidation of the  $\beta$ -keto ester by manganese (III) acetate gives radical **79**. Addition of the radical intermediate to the quinone ring, followed by oxidation, gives **80** (Scheme 35) [56]. Compound **80** underwent condensation to produce **76** (path a). With larger  $R^5$ , **80** undergoes either






Scheme 27




Scheme 28




condensation to generate **76** (path a) or oxidation to produce radical **81**. Radical **81** undergoes either cyclization with ( $R = H, Me, i\text{-Pr}$ ) to give **82**, followed by alkyl group migration and oxidation to produce **77** (path b) or oxidation (with  $R = p\text{-tolyl}$ ) by manganese (III) acetate to produce imine **84**. Imine **84** underwent further intramolecular nucleophilic addition followed by retro-Claisen condensation and oxidation to produce **78** (Scheme 35) [56]. The free radical mechanism might here explained the rather difficulty arises in Scheme 35, where an ethyl group on the nitrogen in **81** somehow becomes a propylidene group (in **84**), thereafter becoming entangled with the incoming diacylmethyl group, the ethyl group eventually winding up on C(2) (**85**  $\rightarrow$  **78**) (Scheme 35) [56]. The proposed free radical mechanism can describe unexpected products formation such as those **77** and **78** (Scheme 35).


Scheme 29




Scheme 30



Scheme 31



Scheme 32




Upon reaction of 2-(substituted-amino)-1,4-naphthoquinone **66a-d** with substituted acetones and manganese (III) acetate in acetic acid at  $45^\circ\text{C}$ , compounds **86** was obtained in good yields (Scheme 36) [57].


Similarly and as mentioned before, initiation occurs with the manganese (III) acetate oxidation of acetone to produce its radical. This radical intermediate underwent intermolecular addition to the quinone ring followed by oxidation process. Most indicative is the high chemoselectivity of that reaction, which was observed in different solvents [57a,b].

Treatment of *N*-substituted 2-amino-1,4-naphthoquinones **66a-d** with 1,3-dione derivatives and manganese


Scheme 33




Scheme 34




Scheme 35




Scheme 36




Scheme 40




Scheme 37




Scheme 41




Scheme 38




Scheme 42




Scheme 39



Scheme 43





(III) acetate at rt gave only one compound **87**, the structure of which is shown in Scheme 37 [58,59].

2.2.2.3. *Synthesis of azepine derivatives.* Vargas's group reacted 2-(2,2-dimethoxyethylamino)-3-(3-methylbut-2-enyl)-naphthalene-1,4-dione (**88**) with a mixture of tetrahydrofuran and 10% H<sub>2</sub>SO<sub>4</sub> in methanol for 1 h. An intramolecular Prins pathway proceeded, to afford compounds **89a,b** and **90a,b** (Scheme 38) [60].

The same group also reported that compound **88** reacted with formic acid at room temperature for 2 h, to afford regioselectively compound **91** (Scheme 39) [60].

2.2.2.4. *Synthesis of indole derivatives.* Reaction of 2-(methylamino)-1,4-naphthoquinone (**66a**) with 1,3-cyclohexanedione and cerium (IV) sulfate in methanol at room temperature gave **92** in 18% yield and no trace of the desired product **93** could be found. A better yield of compound **92** (42%) was obtained when CAN was used (Scheme 40) [61].

2.2.2.5. *Synthesis of quinoline derivatives.* Reaction of 2-(*p*-toluidino)-1,4-naphthoquinone (**66f**) with 2,4-pentanedione in presence of manganese (III) acetate in acetic acid at room temperature afforded compounds **94** and **76** in 77% and 18% yields, respectively (Scheme 41) [56].

2.2.2.6. *Synthesis of 1,4-dihydropyridines.* Upon thermal cyclization of **55** with ethyl 2,2-diethoxyacetate (**95**), 6*H*-dibenzo[*b,i*]carbazole-5,13:7,12-diquinone (**96**) was obtained. This transformation constitutes a new example





of Huntzsch synthesis of 1,4-dihydropyridines [62] and has to involve a nucleophilic substitution of **48** at C-3 [57b]. This means that **48** is acting here as an enamine compound (Scheme 42) [57b].

A plausible reaction mechanism involves C-3-alkylation, ethanol elimination, Michael addition of a second molecule of **55** and cyclization with elimination of ammonia to give **96** as illustrated in Scheme 43 [62].

2.2.2.7. *Synthesis of oxazine, terahydrobenzo[*g*]chinazoline and pyridoacridines derivatives.* Reaction of **55** with **95** catalyzed by H<sub>2</sub>SO<sub>4</sub> afford (±)-*cis*-diethyl-5,8-dioxo-1*H*-2,4-dihydronaphtho[2,3-*d*]1,3-oxazine-2,4-dicarboxylate (**97**) after 6 d (Scheme 44) [62].

Reactions of compound **55** with aldehydes in the presence of a catalytic amount of trifluoroacetic acid at rt produce substituted 1*H*-2-dihydronaphtho-[2,3-*d*]1,3-oxazine-5,10-diones (**98** and **99**) in 54-70% yield as illustrated in Scheme 45 [51].

A plausible reaction mechanism for the formation of the products **98** and **99** involves C-3 alkylation, followed by water elimination to produce the azadiene intermediate (**101**; Scheme 46). This intermediate is reactive enough to produce the cyclized product by trapping another aldehyde molecule, most likely by Diels-Alder reaction [51].



2-Amino-1,4-naphthoquinone (**55**) behaves as a bidentate nucleophile with primary amines and formaldehyde to give 3-substituted 1,2,3,4-tetrahydrobenzo[*g*]chinazoline-5,10-diones **102** in poor to moderate yields (Scheme 47) [50].

Several pyridoacridines **104** were synthesized in a two-step reaction of  $\beta,\beta'$ -diaminoketones (**103a,b**) with 1,4-naphthoquinone (**59**) (Scheme 48). The prepared pyridoacridines showed moderate effect *in vitro* cytotoxicity against P-388 mouse lymphoma cells [63].

#### REFERENCES AND NOTES

- [1] Perry, N. B.; Blunt, J. W.; Munro, M. H. G. *J Nat Prod* 1991, 54, 978.
- [2] Thomson, R. H. *Naturally Occurring Quinones*, 2nd ed.; Academic: London, 1971.
- [3] Didry, N.; Pinkas, M.; Dubreuil, L. *Ann Pharm Fr* 1986, 44, 73.
- [4] Phelps, D. C.; Nemeč, S.; Baker, R.; Mansell, R. *Phytopathology* 1990, 80, 298.
- [5] Papageorgiou, V. P.; Assimopoulou, A. N.; Couladouros, E. A.; Hepworth, D.; Nicolaou, K. C. *Angew Chem Int Ed Engl* 1999, 38, 270.
- [6] Riffel, A.; Medina, L. F.; Stefani, V.; Santos, R. C.; Bizani, D.; Brandelli, A. *Braz J Med Biol Res* 2002, 35, 811.
- [7] Ellison, A. M.; Gotelli, N. J. *J Exp Bot* 2009, 60, 19.
- [8] Rischer, H.; Hamm, A.; Bringmann, G. *Phytochemistry* 2002, 59, 603.
- [9] Bringmann, G.; Feineis, D. *J Exp Bot* 2001, 52, 2015.
- [10] Babula, P.; Adam, V.; Havel, L.; Kizek, R. *Curr Pharm Anal* 2009, 5, 47.
- [11] Akins, R. A. *Med Mycol* 2005, 43, 285.
- [12] Bringmann, G.; Rischer, H.; Wohlfarth, M.; Schlauer, J.; Assi, L. A. *Phytochemistry* 2000, 53, 339.
- [13] Didry, N. I.; Dubreuil, L.; Trotin, F.; Pinkas, M. *J Ethnopharmacol* 1998, 60, 91.
- [14] de Paiva, S. R.; Figueiredo, M. R.; Aragao, T. V.; Kaplan, M. A. C. *Mem Inst Oswaldo Cruz* 2003, 98, 959.
- [15] Bringmann, G.; Wohlfarth, M.; Rischer, H.; Rückert, M.; Schlauer, J. *Tetrahedron Lett* 1998, 39, 8445.
- [16] Dzoyem, J. P.; Tangmouo, J. G.; Lontsi, D.; Etoa, F. X.; Lohoue, P. J. *Phytother Res* 2007, 21, 671.
- [17] Tandon, V. K.; Maurya, H. K.; Tripathi, A.; Shivakeshava, G. B.; Shukla, P. K.; Srivastava, P.; Panda, D. *Eur J Med Chem* 2009, 44, 1086.
- [18] Dulay, I. S.; Gibson, F. D.; Eyeson-Annan, M. B.; Narara, A. *P N G Med J* 1987, 30, 281.
- [19] Das Sarma, M.; Ghosh, R.; Patra, A.; Hazra, B. *Eur J Med Chem* 2008, 43, 1878.
- [20] Kapadia G. J.; Azuine, M. A.; Balasubramanian, V.; Sridhar, R. *Pharmacol Res* 2001, 43, 363.
- [21] Aly, A. A.; El-Shaieb, K. M. *Tetrahedron* 2004, 60, 3797.
- [22] (a) Schellhammer, C. W.; Petersen, S.; Domagk, G. (to Fabrenfabriken Bayer A.-G.) US Pat. 3,084,165, 1963; *Chem Abstr* 1963, 59, 13956e. (b) Fries, K.; Ochwat, P. *Ber Dtsch Chem Ges* 1923, 56B, 1291.
- [23] Remusat, V.; Terme, T.; Gellis, A.; Rathelot, P.; Vanelle, P. *J Heterocycl Chem* 2004, 41, 221.
- [24] (a) Hoover, J. R. E.; Day, A. R. *J Am Chem Soc* 1954, 76, 4148. (b) Lien, J.-C.; Huang, L.-J.; Wang, J.-P.; Teng, C.-M.; Lee, K.-H.; Kuo, S.-C. *Chem Pharm Bull* 1996, 44, 1181. (c) Anaconda, J. R.; Bastardo, E.; Camus, J. *Transit Met Chem* 1999, 24, 478.
- [25] Díaz, R.; Reyes, O.; Francois, A.; Leiva, A. M.; Loeb, B. *Tetrahedron Lett* 2001, 42, 6463.
- [26] Winkelmann, E. *Tetrahedron* 1969, 25, 2427.
- [27] Loskutov, V. A.; Lukonina, S. M.; Korobeinicheva, I. K.; Fokin, E. P. *Zh Org Khim* 1978, 14, 172.
- [28] Krieg, B.; Urban, R. *Liebigs Ann Chem* 1988, 799.
- [29] Kuznetsov, V. S.; Éfros, L. S. *J Org Chem USSR* 1965, 1, 1479.
- [30] Nakamori, T.; Osaki, I.; Kasai, T. *Nippon Kagaku Kaishi* 1982, 450.
- [31] Aly, A. A.; Brown, A. B.; Hasaan, A. A.; El-Shaieb, K. M.; Bedair, T. M. I. *J Heterocycl Chem* 2010, 48, 787.
- [32] Neidlein, R.; Tran-Viet, D.; Gieren, A.; Kokkinidis, M.; Wilckens, R.; Geserich, H.-P.; Ruppel, W. *Chem Ber* 1982, 115, 2898.
- [33] Kublak, G. G.; Confalone, P. N. *Tetrahedron Lett* 1990, 31, 3845.
- [34] Camara, C. A.; Pinto, A. C.; Rosa, M. A. Vargas, M. D. *Tetrahedron* 2001, 57, 9569.
- [35] Yamashita, Y.; Tsubata, Y.; Suzuki, T.; Miyashi, T.; Mukai, T.; Tanaka, S. *Chem Lett* 1990, 445.
- [36] Giorgi-Renault, S.; Renault, J.; Baron, M.; Servolles, P.; Paoletti, C.; Cros, S. *Eur J Med Chem* 1985, 20, 144.
- [37] Anzenbacher, P., Jr.; Palacios, M. A.; Jursiková, K.; Marquez, M. *Org Lett* 2005, 7, 5027.
- [38] Chung, W.-S.; Liu, J.-H. *Chem Commun* 1997, 205.
- [39] Efimova, G. A.; Efros, L. S. *Zh Org Khim* 1966, 2, 531.
- [40] Haug, J.; Scheffler, K.; Stegmann, H. B.; Vonwirth, S.; Weiß, J. E.; Conzelmann, W.; Hiller, W. *Chem Ber* 1987, 120, 1125.
- [41] Katritzky, A. R.; Fan, W.-Q.; Li, Q.-L.; Bayyuk, S. *J Heterocycl Chem* 1989, 26, 885.
- [42] Phutdhawong, P. S.; Ruensamran, W.; Phutdhawong, W.; Taechowisan, T. *Biorg Med Chem Lett* 2009, 19, 5753.
- [43] Wang, X. L.; Zheng, X. F.; Liu, R. H.; Reiner, J.; Chang, J. B. *Tetrahedron* 2007, 63, 3389.
- [44] (a) Marcos, A.; Pedregal, C.; Avendano, C. *Tetrahedron* 1994, 50, 12941. (b) *Tetrahedron* 1995, 51, 1763.
- [45] Pettit, G. R.; Fleming, W. C.; Paul, K. D. *J Org Chem* 1968, 33, 1089.
- [46] Dähne, S.; Ranft, J.; Paul, H. *Tetrahedron Lett* 1964, 5, 3355.
- [47] Driebergen, R. J.; den Hartigh, J.; Holthuis, J. J. M.; Hulshoff, A.; Van Oort, W. J.; Kelder, S. J. P.; Verboom, W.; Reinhoudt, D. N.; Bos, M.; Van Der Linden, W. E. *Anal Chim Acta* 1990, 233, 351.
- [48] Hamdan, A. J.; Moore, H. W. *J Org Chem* 1985, 50, 3427.
- [49] Corey, E. J.; Clark, D. A. *Tetrahedron Lett* 1980, 21, 2045.
- [50] Möhrle, H.; Herbrüggen, G. S. *Arch Pharm* 1991, 324, 165.
- [51] Hamdan, A. J.; Al-Jaroudi, S. *Arabian J Sci Eng Sect A* 2003, 28, 51.
- [52] Couladouros, E. A.; Plyta, Z. F.; Haroutounian, S. A.; Papageorgiou, V. P. *J Org Chem* 1997, 62, 6.
- [53] Boulos, L. S.; Arsanious, M. H. N. *Tetrahedron* 1997, 53, 3649.
- [54] Bestmann, H. J.; Lang, H. J. *Tetrahedron Lett* 1969, 10, 2101.
- [55] Chuang, C.-P.; Wang, S.-F. *Tetrahedron* 1998, 54, 10043.
- [56] Jiang, M.-C.; Chuang, C.-P. *J Org Chem* 2000, 65, 5409.
- [57] (a) Wu, Y.-L.; Chuang, C.-P.; Lin, P.-Y. *Tetrahedron* 2001, 57, 5543. (b) Marcos, A.; Pedregal, C.; Avendano, C. *Tetrahedron* 1995, 51, 6565.
- [58] Chuang, C.-P.; Wang, S.-F.; Lee, J.-H. *Heterocycles* 1999, 50, 489.
- [59] Tseng, C.-C.; Wu, Y.-L.; Chuang, C.-P. *Tetrahedron* 2002, 58, 7625.
- [60] Camara, C. A.; Pinto, A. C.; Vargas, M. D.; Zukerman-Schpector, J. *Tetrahedron* 2002, 58, 6135.
- [61] Bossert, F.; Meyer, H.; Wehinger, E. *Angew Chem Int Ed Engl* 1981, 20, 762.
- [62] Martins, F. J. C.; Viljoen, A. M.; Strydom, S. J.; Fourie, L.; Wessels, P. L. *Tetrahedron* 1988, 44, 591.
- [63] Koller, A.; Rudi, A.; Gravalos, M. G.; Kashman, Y. *Molecules* 2001, 6, 300.